Pfizer / Merck bavencio research and development daily failed in the maintenance treatment of refractory gastric cancer

Pfizer / Merck bavencio research on maintenance treatment of refractory gastric cancer failed! ; the first new acne drug with new mechanism in 40 years! FDA accepts clascoterone new drug application; Ebola vaccine! J & J's 2-dose vaccine program entered the accelerated evaluation in the EU! The safety test results of losartan are positive, and it is expected to submit new drug application in the United States this year We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel Recently, Pfizer and Merck said that in a three-stage maintenance treatment study (javelin gastric 100), after a successful round of chemotherapy for patients with gastric cancer who are in advanced stage or unable to undergo surgery, bavencio failed to beat the other two treatment options compared with the best support treatment for continuing chemotherapy or prolonging patients' lives The study found that bavencio did not show a good treatment advantage even in PD-1 / L1 positive patients who had historically shown better efficacy of PD-1 / L1 inhibitors Recently, gene Taike published the latest clinical results of gazyva (obinutuzumab) in the treatment of proliferative lupus nephritis The trial reached the primary end point, and between 52 and 76 weeks of treatment, the proportion of patients who achieved complete renal remission in the combination of gazyva and standard care was significantly higher than that in the control group Gazayva also reached a critical secondary efficacy endpoint Recently, Abercrombie announced that it has submitted a new drug supplement application to the U.S FDA, which will target the anticancer drug imbruvica (ibrutinib, elutinib) and rituximab (rituximab) for the first-line treatment of chronic lymphoblastic leukemia or small lymphoid lymphoma in younger patients (< 70 years old) Recently, Cassiopea spa, a pharmaceutical company focused on skin diseases, announced that the FDA of the United States has accepted the application of its clascoterone (1% concentration) cream for the treatment of acne The date of PDUFA is August 27, 2020 It is worth mentioning that this is the first new mechanism drug for acne treatment in recent 40 years Clascoterone (also known as cb-03-01) is a local androgen receptor inhibitor, and the new chemical entity is developing treatments for acne (tentatively named winlevi) and male and female hair loss (tentatively named breezula) Recently, Johnson & Johnson's Janssen Pharmaceutical Company announced that it has submitted two marketing authorization applications (MAA) to the European Drug Administration (EMA) for approval of the research-based Ebola vaccine program to prevent Ebola virus disease caused by the Zaire Ebola virus strain Two Maas have been submitted in parallel to support each vaccine (ad26.zebov, mva-bn-filo) In September, the EMA Committee on human pharmaceutical products awarded these applications accelerated assessment qualifications A few days ago, AstraZeneca and fabergin announced the summary efficacy and cardiovascular (CV) safety analysis of roxadustat Losartan is a "first in class" inhibitor of prolyl hydroxylase, a hypoxia inducible factor A pooled CV safety analysis showed that rosaristad did not increase major cardiovascular adverse events and all-cause mortality compared to placebo in patients with non dialysis dependent renal anemia Compared with the current standard therapy, erythropoietin did not improve mace and all-cause mortality in patients with dialysis dependent renal anemia On November 9, shengjitang announced that its wholly-owned subsidiary, shengjitang pharmaceutical, had received the approval document for supplementary drug application issued by the State Food and Drug Administration on glimepiride tablets (2mg), which passed the consistency evaluation of quality and efficacy of generic drugs According to the data of minenet, in 2018, among the top 20 generic names of terminal oral diabetes drugs in public medical institutions in China, glimepiride ranked the third with a sales volume of 2.4 billion yuan Recently, Zhao Fengguang, Secretary of jiankangyuan, revealed that tobramycin inhalation solution of the company is expected to become the first inhaled antibiotic drug in China The data shows that the clinical application of class 2.4 new drug of tobramycin inhalation solution of jiankangyuan was approved in October 2017, and now it has entered into phase III clinical.